NYSEAMERICAN:NBY NovaBay Pharmaceuticals (NBY) Stock Price, News & Analysis → Claim Your Complimentary Bitcoin Reward (From Crypto Swap Profits) (Ad) Free NBY Stock Alerts $3.44 -0.21 (-5.75%) (As of 05/31/2024 ET) Add Compare Share Share Today's Range$3.08▼$3.5550-Day Range N/A52-Week Range$2.28▼$44.80Volume311,805 shsAverage Volume212,749 shsMarket Capitalization$14.48 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestStock AnalysisChartEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort Interest Get NovaBay Pharmaceuticals alerts: Email Address Ad Crypto Swap ProfitsClaim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.Secure Your Spot Now About NovaBay Pharmaceuticals Stock (NYSEAMERICAN:NBY)NovaBay Pharmaceuticals, Inc. develops and sells eyecare and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; Avenova Eye Health Support antioxidant-rich oral supplements; Avenova Lubricating Eye Drops for instant relief; NovaWipes by Avenova; Avenova WarmEye Compress to soothe the eyes; and the i-Chek by Avenova to monitor physical eyelid health. The company also provides wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands. It sells its products through the company's web stores, third-party online retailers and distribution partners. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.Read More NBY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NBY Stock News HeadlinesMay 20, 2024 | msn.comNovaBay Pharmaceuticals Stock Is Up 50%: What's Going On?May 13, 2024 | finance.yahoo.comNovaBay Pharmaceuticals, Inc. (AMEX:NBY) Q1 2024 Earnings Call TranscriptMay 8, 2024 | markets.businessinsider.comNovaBay Pharmaceuticals is about to announce earnings — here's what Wall Street expectsApril 17, 2024 | finance.yahoo.comNovaBay Pharmaceuticals Reports Preliminary Eyecare and Wound Care Revenue Increased 13% for the First Quarter of 2024 on Lower Sales and Marketing ExpensesApril 17, 2024 | markets.businessinsider.comBuy Rating Maintained for NovaBay Pharma Amid Strategic Refocus and Resilient Revenue PerformanceMarch 27, 2024 | finance.yahoo.comNovaBay Pharmaceuticals, Inc. (AMEX:NBY) Q4 2023 Earnings Call TranscriptMarch 27, 2024 | finance.yahoo.comQ4 2023 NovaBay Pharmaceuticals Inc Earnings CallMarch 15, 2024 | barrons.comNovaBay Pharmaceuticals Inc.March 14, 2024 | markets.businessinsider.comNovaBay Pharmaceuticals To Sell DERMAdoctor Skincare Business - Quick FactsMarch 13, 2024 | markets.businessinsider.comNovaBay Pharmaceuticals and Eyenovia to Co-Promote Prescription Ophthalmic Products to U.S. Eyecare ProfessionalsFebruary 26, 2024 | finance.yahoo.comNovaBay Pharmaceuticals, Inc. (NBY)January 30, 2024 | finance.yahoo.comNovaBay Pharmaceuticals Reports 64% Year-Over-Year Growth in Avenova Unit Subscription-Based SalesJanuary 29, 2024 | msn.comWhy ZIM Integrated Shipping Services Shares Are Trading Higher By 9%; Here Are 20 Stocks Moving PremarketJanuary 9, 2024 | finance.yahoo.comNovaBay Pharmaceuticals and Sonoma Pharmaceuticals Agree to Market Avenova-branded Products in the European Union Through Sonoma’s Extensive Distributor NetworkDecember 6, 2023 | finance.yahoo.comNovaBay Pharmaceuticals Partners with Woo University to Educate Eyecare Professionals on the Use of Amniotic MembranesNovember 12, 2023 | finance.yahoo.comNovaBay Pharmaceuticals, Inc. (AMEX:NBY) Q3 2023 Earnings Call TranscriptNovember 9, 2023 | benzinga.comRecap: NovaBay Pharmaceuticals Q3 EarningsNovember 9, 2023 | finance.yahoo.comNovaBay Pharmaceuticals Reports Third Quarter 2023 Financial ResultsNovember 2, 2023 | finance.yahoo.comNovaBay Pharmaceuticals to Hold Third Quarter 2023 Conference Call on November 9, 2023October 21, 2023 | thestreet.comNovaBay Pharmaceuticals: CEO InterviewOctober 11, 2023 | finance.yahoo.comNovaBay Pharmaceuticals Expands Physician Dispensed Sales Channel with New Avenova ProgramsOctober 2, 2023 | finance.yahoo.comNovaBay Pharmaceuticals to Present at the Dawson James Small Cap Growth ConferenceSeptember 11, 2023 | marketwatch.comNovaBay Pharma Shares Rise 42% After Deal With BioStem TechnologiesSeptember 11, 2023 | markets.businessinsider.comNovaBay Pharma Agrees With BioStem To Commercialize Amniotic Tissue Allograft As Avenova AllograftSeptember 11, 2023 | benzinga.comWhy NovaBay Pharmaceuticals Stock Is Blasting HigherSee More Headlines Receive NBY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NovaBay Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today6/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNYSEAMERICAN:NBY CUSIPN/A CIK1389545 Webnovabay.com Phone(510) 899-8800Fax510-474-1577Employees24Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($9.9465) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-10,610,000.00 Net Margins-79.70% Pretax Margin-79.70% Return on Equity-146.20% Return on Assets-69.63% Debt Debt-to-Equity RatioN/A Current Ratio1.85 Quick Ratio1.25 Sales & Book Value Annual Sales$14.40 million Price / Sales1.01 Cash FlowN/A Price / Cash FlowN/A Book Value$1.53 per share Price / Book2.25Miscellaneous Outstanding Shares4,210,000Free Float4,160,000Market Cap$14.48 million OptionableNot Optionable Beta2.82 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMr. Justin M. Hall Esq. (Age 46)President, CEO, General Counsel, Chief Compliance Officer, Corporate Secretary & Director Comp: $364.15kMr. Tommy Law (Age 39)Controller, Interim CFO & Treasurer Comp: $177.7kKey CompetitorsNeuBase TherapeuticsNASDAQ:NBSE9 Meters BiopharmaNASDAQ:NMTRHemispherx BioPharmaNYSEAMERICAN:HEBPolarityTENASDAQ:PTEIQAsterias BiotherapeuticsNYSEAMERICAN:ASTView All Competitors NBY Stock Analysis - Frequently Asked Questions How have NBY shares performed in 2024? NovaBay Pharmaceuticals' stock was trading at $0.1802 at the beginning of the year. Since then, NBY shares have increased by 1,809.0% and is now trading at $3.44. View the best growth stocks for 2024 here. Are investors shorting NovaBay Pharmaceuticals? NovaBay Pharmaceuticals saw a decrease in short interest during the month of May. As of May 15th, there was short interest totaling 30,500 shares, a decrease of 77.7% from the April 30th total of 137,000 shares. Based on an average daily volume of 8,110,000 shares, the short-interest ratio is presently 0.0 days. Currently, 0.1% of the company's stock are short sold. View NovaBay Pharmaceuticals' Short Interest. How were NovaBay Pharmaceuticals' earnings last quarter? NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) issued its quarterly earnings data on Thursday, May, 9th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter. The biopharmaceutical company earned $2.63 million during the quarter. NovaBay Pharmaceuticals had a negative net margin of 79.70% and a negative trailing twelve-month return on equity of 146.20%. When did NovaBay Pharmaceuticals' stock split? Shares of NovaBay Pharmaceuticals reverse split on the morning of Wednesday, November 16th 2022. The 1-35 reverse split was announced on Wednesday, November 16th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, November 16th 2022. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. What other stocks do shareholders of NovaBay Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other NovaBay Pharmaceuticals investors own include Aeterna Zentaris (AEZS), Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), Bionano Genomics (BNGO), Heat Biologics (HTBX), iBio (IBIO), Matinas BioPharma (MTNB), Novan (NOVN), ADMA Biologics (ADMA) and Vaxart (VXRT). How do I buy shares of NovaBay Pharmaceuticals? Shares of NBY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSEAMERICAN:NBY) was last updated on 6/2/2024 by MarketBeat.com Staff From Our PartnersDems have chosen Biden replacement?Paradigm PressThe #1 Crypto That You Don’t Own… YetCrypto 101 MediaBiden Nomination CANCELED?The Freeport SocietyWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersHe Is Giving Away BitcoinCrypto Swap ProfitsThe Worst is Yet to Come…Porter & CompanyThis unknown company solves the biggest issue with AIManward Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NovaBay Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
